U.S. markets open in 1 hour 39 minutes
  • S&P Futures

    4,294.50
    -3.75 (-0.09%)
     
  • Dow Futures

    33,867.00
    -6.00 (-0.02%)
     
  • Nasdaq Futures

    13,668.50
    -12.75 (-0.09%)
     
  • Russell 2000 Futures

    2,022.40
    -1.40 (-0.07%)
     
  • Crude Oil

    90.09
    +0.68 (+0.76%)
     
  • Gold

    1,791.20
    -6.90 (-0.38%)
     
  • Silver

    20.07
    -0.20 (-1.00%)
     
  • EUR/USD

    1.0130
    -0.0035 (-0.34%)
     
  • 10-Yr Bond

    2.7910
    0.0000 (0.00%)
     
  • Vix

    20.02
    +0.49 (+2.51%)
     
  • GBP/USD

    1.2020
    -0.0038 (-0.32%)
     
  • USD/JPY

    134.4280
    +1.1560 (+0.87%)
     
  • BTC-USD

    24,052.10
    -61.81 (-0.26%)
     
  • CMC Crypto 200

    572.94
    -17.82 (-3.02%)
     
  • FTSE 100

    7,562.51
    +53.36 (+0.71%)
     
  • Nikkei 225

    28,868.91
    -2.87 (-0.01%)
     

G1 Therapeutics to Provide Fourth Quarter and Full Year 2021 Financial Results and Business Update on February 23, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2021 on Wednesday, February 23, 2022 at 8:30 a.m. ET.

The live call may be accessed by dialing (866) 763-6020 (domestic) or (409) 216-0626 (international) and entering the conference code: 5256086. The live and archived webcast will be available on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics™ and the G1 Therapeutics logo are trademarks of G1 Therapeutics, Inc.

G1 Therapeutics Contacts:

Will Roberts
Vice President
Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com

Rebecca Levine
Director, Corporate Communications and Public Relations
(919) 667-8711
rlevine@g1therapeutics.com